Cynata Therapeutics Limited (FRA:51S)

Market Cap	1.82M -94.0%
Revenue (ttm)	1.04M -9.2%
Net Income	-5.60M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	0.0060
Previous Close	0.0070
Day's Range	0.0060 - 0.0060
52-Week Range	0.0005 - 0.2400
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51S

Financial Performance

In fiscal year 2026, Cynata Therapeutics's revenue was 1.71 million, a decrease of -9.20% compared to the previous year's 1.89 million. Losses were -9.25 million, -1.51% less than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 13, 2026

Data Sources Report a data error